Lista de obras - Leo Gordon - Dominio Público Uruguay

A VM 26-based regimen for patients with previously untreated non-Hodgkin lymphoma. Prolonged disease-free survival in patients younger than 60 years of age: a phase II trial of the eastern Cooperative Oncology Group

scientific article published on 01 January 1993

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.

artículo científico publicado en 2013

A novel approach to safer glucocorticoid receptor-targeted anti-lymphoma therapy via REDD1 (Regulated in development and DNA damage 1) inhibition

artículo científico publicado en 2020

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

scientific article published on 29 April 2007

A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas

artículo científico publicado en 2013

A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma

artículo científico publicado en 2007

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

artículo científico publicado en 2004

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.

artículo científico publicado en 2011

Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).

artículo científico publicado en 2012

Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?

artículo científico publicado en 2008

Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study

artículo científico publicado en 1995

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

artículo científico publicado en 2013

Bacterial phosphatidylcholine-preferring phospholipase C reversibly inhibits the membrane component of the NADPH oxidase in human polymorphonuclear leukocytes: implications for host defense

artículo científico publicado en 1993

Benign hepatic cyst in a patient on antiestrogen therapy for metastatic breast cancer

scientific article published on 01 November 1982

Biomimetic, synthetic HDL nanostructures for lymphoma ⬇️

artículo científico publicado el 23 de enero de 2013

Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways

artículo científico publicado en 2008

Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation

artículo científico publicado en 2012

Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole

artículo científico publicado en 2007

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

scientific article published on 07 January 2019

CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease

artículo científico publicado en 2008

CD34(+) cell collection efficiency does not correlate with the pre-leukapheresis hematocrit

artículo científico publicado en 2001

Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?

artículo científico publicado en 2005

Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: response to chemotherapy in two cases

artículo científico publicado en 1979

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

artículo científico publicado en 2001

Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemia

artículo científico publicado en 2011

Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

artículo científico publicado en 2012

Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network

artículo científico publicado en 2014

Curcumin nanodisk-induced apoptosis in mantle cell lymphoma ⬇️

artículo científico publicado el 24 de junio de 2011

Curcumin nanodisks: formulation and characterization

artículo científico publicado en 2010

Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A ⬇️

artículo científico publicado el 16 de mayo de 2012

Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs

artículo científico publicado en 2010

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

artículo científico publicado en 2013

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

artículo científico publicado en 2006

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

artículo científico publicado en 2004

Evaluation of computed tomography and radionuclide scanning in the staging of cutaneous T-cell lymphoma

scientific article published on 01 August 1986

Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies.

artículo científico publicado en 2003

F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma

artículo científico publicado en 2014

Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma

scientific article published on 01 April 2003

Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.

artículo científico publicado en 2004

Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study

artículo científico publicado en 2014

G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis

artículo científico publicado en 2007

Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and . . ⬇️

artículo científico publicado el 1 de noviembre de 2001

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma

artículo científico publicado en 2012

Genetic heterogeneity of diffuse large B-cell lymphoma

artículo científico publicado en 2013

Getting to transplant in Hodgkin lymphoma: BVB

artículo científico publicado en 2018

Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms

artículo científico publicado en 2010

Haematological cancer: Indolent lymphoma--why not to sprint at the start of a marathon

artículo científico publicado en 2013

High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database.

artículo científico publicado en 2012

How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?

artículo científico publicado en 2004

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

artículo científico publicado en 2002

Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review

artículo científico publicado en 2020

Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?

artículo científico publicado en 2004

Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?

artículo científico publicado en 2003

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

artículo científico publicado en 2006

Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent.

artículo científico publicado en 2004

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma

artículo científico publicado en 2018

Inhibition of cytolytic T lymphocyte activity by oxysterols

artículo científico publicado en 1994

Inhibition of human polymorphonuclear leukocyte respiratory burst activity and aggregation by 6-ketocholestanol

artículo científico publicado en 1990

Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database

artículo científico publicado en 2011

Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma

scientific article published on 01 March 1998

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

artículo científico publicado en 2007

MDCT of chest, abdomen, and pelvis using attenuation-based automated tube voltage selection in combination with iterative reconstruction: an intrapatient study of radiation dose and image quality

artículo científico publicado en 2013

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

artículo científico publicado en 2009

Management of early-stage Hodgkin's lymphoma. The radiation oncology experience at Northwestern University/Northwestern Memorial Hospital

artículo científico publicado en 1996

Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata ⬇️

artículo científico publicado en 2010

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

artículo científico publicado en 2007

Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells

artículo científico publicado en 2004

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

artículo científico publicado en 2010

Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo

artículo científico publicado en 2013

Off-targeting oft-targeted CD20 in cHL

artículo científico publicado en 2012

Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation.

artículo científico publicado en 2009

Paradoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphoma

artículo científico publicado en 2013

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

artículo científico publicado en 2009

Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes

scientific article published on 25 February 2013

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma

artículo científico publicado en 2020

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

artículo científico publicado en 2012

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

artículo científico publicado en 2005

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma

artículo científico publicado en 2007

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

artículo científico publicado en 2013

Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.

artículo científico publicado en 2010

Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era.

artículo científico publicado en 2013

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

artículo científico publicado en 2009

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.

artículo científico publicado en 2008

Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.

artículo científico publicado en 2010

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

artículo científico publicado en 2002

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

artículo científico publicado en 2012

Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea

artículo científico publicado en 2002

Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 10(9)/l neutrophils on 3 consecutive days to define myeloid recovery.

artículo científico publicado en 2002

Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop

artículo científico publicado en 2013

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia.

artículo científico publicado en 2006

Revving up the immune engine in cHL

scientific article published on 01 July 2019

Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis

artículo científico publicado en 2006

Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma

artículo científico publicado en 2007

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

artículo científico publicado en 2003

Scavenging of superoxide anion by phosphorylethanolamine: studies in human neutrophils and in a cell free system

artículo científico publicado en 1991

Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma

artículo científico publicado en 2002

Small-cell carcinoma of the lung: a five-year experience with combined modality therapy

artículo científico publicado en 1980

Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma

article

Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation.

artículo científico publicado en 2012

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.

artículo científico publicado en 2013

Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum

artículo científico publicado en 2006

Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma

artículo científico publicado en 2007

Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis

artículo científico publicado en 2020

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

artículo científico publicado en 2013

The genetic landscape of mutations in Burkitt lymphoma

artículo científico publicado en 2012

The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma

artículo científico publicado en 2011

The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.

artículo científico publicado en 2009

Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database

artículo científico publicado en 2013

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

artículo científico publicado en 2002

Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy

artículo científico publicado en 2007

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

artículo científico publicado en 2012

Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF.

artículo científico publicado en 2005

Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database

artículo científico publicado en 2012

Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

artículo científico publicado en 2007

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

artículo científico publicado en 2009

Lista de obras de Leo Gordon

A VM 26-based regimen for patients with previously untreated non-Hodgkin lymphoma. Prolonged disease-free survival in patients younger than 60 years of age: a phase II trial of the eastern Cooperative Oncology Group

A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.

A novel approach to safer glucocorticoid receptor-targeted anti-lymphoma therapy via REDD1 (Regulated in development and DNA damage 1) inhibition

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas

A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.

Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).

Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?

Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Bacterial phosphatidylcholine-preferring phospholipase C reversibly inhibits the membrane component of the NADPH oxidase in human polymorphonuclear leukocytes: implications for host defense

Benign hepatic cyst in a patient on antiestrogen therapy for metastatic breast cancer

Biomimetic, synthetic HDL nanostructures for lymphoma ⬇️

Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways

Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation

Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease

CD34(+) cell collection efficiency does not correlate with the pre-leukapheresis hematocrit

Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?

Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: response to chemotherapy in two cases

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemia

Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network

Curcumin nanodisk-induced apoptosis in mantle cell lymphoma ⬇️

Curcumin nanodisks: formulation and characterization

Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A ⬇️

Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

Evaluation of computed tomography and radionuclide scanning in the staging of cutaneous T-cell lymphoma

Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies.

F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma

Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma

Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.

Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study

G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis

Gemtuzumab Ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and . . ⬇️

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma

Genetic heterogeneity of diffuse large B-cell lymphoma

Getting to transplant in Hodgkin lymphoma: BVB

Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms

Haematological cancer: Indolent lymphoma--why not to sprint at the start of a marathon

High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database.

How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review

Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?

Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent.

In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma

Inhibition of cytolytic T lymphocyte activity by oxysterols

Inhibition of human polymorphonuclear leukocyte respiratory burst activity and aggregation by 6-ketocholestanol

Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database

Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

MDCT of chest, abdomen, and pelvis using attenuation-based automated tube voltage selection in combination with iterative reconstruction: an intrapatient study of radiation dose and image quality

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

Management of early-stage Hodgkin's lymphoma. The radiation oncology experience at Northwestern University/Northwestern Memorial Hospital

Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata ⬇️

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo

Off-targeting oft-targeted CD20 in cHL

Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation.

Paradoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphoma

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.